Cladribine therapy in adults with advanced Langerhans cell histiocytosis

Leukemia and Lymphoma

Volumn 54, Issue 7, 2013, Pages 1541-1543

  Schini, Marian ^a   Makras, Polyzois ^b   Kanakis, George ^a   Voulgarelis, Michael ^a   Kaltsas, Gregory ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CLADRIBINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; HYDROXYUREA; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; VALACICLOVIR; VINBLASTINE;

BONE MARROW SUPPRESSION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL FEATURE; DOSE RESPONSE; DRUG EFFICACY; HUMAN; INCIDENCE; LANGERHANS CELL; LANGERHANS CELL HISTIOCYTOSIS; LETTER; MASTOIDECTOMY; MORTALITY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PNEUMOTHORAX; PRACTICE GUIDELINE; PRIORITY JOURNAL; THORAX DRAINAGE; THROMBOCYTOPENIA; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CLADRIBINE; FEMALE; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; LUNG; MALE; MIDDLE AGED; SKULL; YOUNG ADULT;

EID: 84879376143     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.744454     Document Type: Letter

References (14)

1. Baumgartner I, Hochstetter A, Baumert B, et al. Langerhans '-cell histiocytosis in adults. Med Pediatr Oncol 1997;28:9-14.
2. Arico M, Girschikofsky M, Genereau T, et al. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer 2003;39:2341-2348. (Pubitemid 37214858)
3. Makras P, Piaditis G, Kaltsas G. Systemic and endocrine manifestations of Langerhans ' cell histiocytosis: current concepts in diagnosis and management. Expert Rev Endocrinol Metab 2007 ; 2:773-783. (Pubitemid 350111121)
4. Tatevossian R, Nanduri V, Salotti J, et al. Adults with LCH-orphans with an orphan disease. Clin Med 2006;6:404-408.
5. Nezelof C, Frileux-Herbet F, Cronier-Sachot J. Disseminated histiocytosis X. Analysis of prognostic factors based on a retrospective study of 50 cases. Cancer 1979; 44: 1824-1838. (Pubitemid 10141962)
6. Saven A, Burian C. Cladribine activity in adult Langerhans cell histiocytosis. Blood 1999;93:4125-4130. (Pubitemid 29279254)
7. Biswas G, Khadwal A, Arora B, et al. Activity and toxicity of 2-CDA in Langerhans cell histiocytosis: a single institutional experience. Indian J Cancer 2007;44:137-141
8. Mottl H, Star ý J, Ch á nov á M, et al. Treatment of recurrent Langerhans cell histiocytosis in children with 2- chlorodeoxyadenosine. Leuk Lymphoma 2006; 47: 1881-1884. (Pubitemid 44649773)
9. Stine KC, Saylors RL, Saccente S, et al. Efficacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis. Pediatr Blood Cancer 2004;43:81-84. (Pubitemid 38738277)
10. Saven A, Rosenblatt JD. 2-Chlorodeoxyadenosine to treat refractory histiocytosis X. N Engl J Med 1993; 329: 734-735.
11. Grau J, Ribera JM, Tormo M, et al. Results of treatment with 2-chlorodeoxyadenosine in refractory or relapsed Langerhans cell histiocytosis. Study of 9 patients. Med Clin (Barc) 2001;116:339-342.
12. P ardanani A, P hyliky R L, L i C Y, et al. 2-Chlorodeoxyadenosine therapy for disseminated Langerhans cell histiocytosis. Mayo Clin Proc 2003;78:301-306. (Pubitemid 36259298)
13. Nichols KE, Arceci RJ. BRAF, a piece of the LCH puzzle. Blood 2010;116:1825-1827.
14. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010; 116: 1919-1923.